首页 | 官方网站   微博 | 高级检索  
     


Combined Use of Immunoreactivities of RIG-I with Efp/TRIM25 for Predicting Prognosis of Patients With Estrogen Receptor-positive Breast Cancer
Affiliation:1. Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan;2. Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan;3. Department of Pathology, Toranomon Hospital, Tokyo, Japan;4. Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan;5. Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan;1. Key Laboratory of Tropical Marine Bio-resources and Ecology, South China Sea Institute of Oceanology, Chinese Academy of Sciences, 164 West Xingang Road, Guangzhou 510301, China;2. University of Chinese Academy of Sciences, Beijing, China;1. State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China;2. Department of Gynecological Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China;1. Departments of Microbiology, Kidwai Memorial Institute of Oncology, Bangalore, India;2. National Institute of Biomedical Genomics, Kalyani, West Bengal, India;3. Departments of Microbiology, Indira Gandhi Institute of Child Health, Bangalore, India;4. Biological Data Analyzers’ Association (BdataA), Electronic City, Phase I, Bangalore, India;5. Departments of Pediatric Oncology, Kidwai Memorial Institute of Oncology, India;6. Departments of Pathology, Kidwai Memorial Institute of Oncology, Bangalore, India;7. MedGenome Labs Ltd., Bangalore, India;8. Institute of Bioinformatics and Applied Biotechnology, Bangalore, India;2. State Key Laboratory of Molecular Oncology, Cancer Institute Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China;3. University of the Chinese Academy of Sciences Beijing China;4. The Center for Cell Biology and Cancer Research Albany Medical College Albany NY;5. Wadsworth Center, New York State Department of Health Albany NY;11. Department of Biomedical Sciences, School of Public Health, University at Albany State University of New York Albany NY;1. Department of Pediatric Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, P.R. China;2. Clinical Center of Human Genomic Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, P.R. China;3. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan 430022, Hubei Province, P.R. China
Abstract:BackgroundWe previously identified estrogen-responsive finger protein (Efp) as an estrogen-induced gene, and showed that the positive immunoreactivity of Efp is a poor prognostic factor for patients with breast cancer. We also demonstrated that Efp has distinctive roles in innate immunity by activating pattern recognition receptor retinoic acid-inducible gene I (RIG-I). The clinical value of RIG-I protein expression in breast cancer had not been evaluated in relationship with patients’ prognosis.Patients and MethodsTissue samples of estrogen receptor-positive invasive breast cancer were obtained from 145 female patients with breast cancer who underwent surgical treatment. Immunoreactivities of RIG-I and Efp were analyzed with the antibodies generated for the present study.ResultsPositive immunoreactivity of RIG-I was correlated with lower disease-free survival (P = .032) and was an independent poor prognostic factor (P = .043). RIG-I immunoreactivity was positively correlated with that of Efp (P = .0004). Patients with positive immunoreactivities of both RIG-I and Efp proteins were associated with a lower disease-free survival rate (P = .005).ConclusionsPositive immunoreactivity of RIG-I has clinical significance as a poor prognostic factor in patients with estrogen receptor-positive breast cancer. A positive correlation of RIG-I and Efp immunoreactivities was observed, and the combination of their immunoreactivities can be used to predict patients’ prognosis.
Keywords:Estrogen-responsive finger protein  Immunoreactivity  Pattern recognition receptor  Prognostic factor  Retinoic acid-inducible gene I
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号